Ask which T-cell therapy format is superior and you will get a confident answer from almost everyone in the field — and a different answer from almost everyone you ask. The debate generates heat because it misframes the question. Format is not the variable that determines whether a patient responds. Biology is.
The CAR-T versus T-cell engager framing treats two delivery mechanisms as if they are competing products in the same product category. They are not. They are tools designed for partially overlapping biological problems, each with genuine advantages and genuine constraints. Which one belongs in a given clinical context depends entirely on what that disease biology requires at that stage of treatment.
What CAR-T does that T-cell engagers cannot
CAR-T programmes T cells ex vivo with synthetic antigen-recognition machinery, then returns those engineered cells to the patient. The process is patient-specific: cells are collected, engineered, expanded, and reinfused — a manufacturing cycle that takes weeks. For the right patient in the right clinical setting, this constraint is real but manageable. What it delivers in return is a living therapy. CAR-T cells can persist, proliferate, and — in some patients — produce responses that are deep and durable in a way that no fixed-dose molecule can replicate through pharmacokinetics alone.
In haematological malignancies where a defined patient population can tolerate the manufacturing window and the toxicity profile, CAR-T has produced outcomes that redefined clinical expectations for what T-cell therapies can achieve. That record is not diminished by the existence of alternative formats.
What T-cell engagers do differently
T-cell engagers — bispecifics, trispecifics, and related formats — redirect endogenous T cells already present in the patient. The molecule does the bridging: one arm engages a tumour antigen, another engages CD3 on T cells, and the proximity drives a killing response. No ex vivo manufacturing. No patient-specific production cycle. The therapy is produced at scale and administered off-the-shelf — monthly dosing, accessible to patients for whom the CAR-T manufacturing window is not an option.
The clinical record in this format is now substantial. Published Phase 1 data for next-generation multispecific T-cell engagers in relapsed and refractory multiple myeloma have shown overall response rates exceeding 85% at recommended Phase 2 doses — off-the-shelf, monthly dosing, in patient populations that represent one of the most difficult disease settings in haematology.
That result does not mean T-cell engagers beat CAR-T. It means that in this indication, at this stage of disease, a well-designed off-the-shelf molecule can generate deep responses in the biology where it must work.
The shared vulnerability both formats carry
The format debate often obscures the more important structural problem that both approaches face: antigen escape. Under the selective pressure of a therapy that targets a specific antigen, tumour cells that downregulate or lose that antigen survive. They repopulate. The patient relapses. This pattern has been observed consistently across targeted myeloma therapies — in CAR-T programmes and in T-cell engager programmes alike.
Antigen escape is not a format problem. Switching from CAR-T to a bispecific — or the reverse — does not address the underlying vulnerability if the replacement therapy targets the same single antigen. The question is whether the molecule was designed with escape in mind, not which delivery mechanism carries it.
The right question
What does the disease biology require at this stage of treatment? For a patient with newly diagnosed myeloma who can tolerate the manufacturing window and access a specialist centre, a CAR-T programme with curative intent may be the right tool. For a patient with relapsed disease who cannot wait weeks, who is not eligible for a specialist centre, or whose tumour has already shed the primary target — the clinical requirements are different. The answer is different.
Within T-cell engager design, the question becomes more specific: which antigen, engaged how, by a molecule designed for what escape scenario? Format determines access and logistics. Antigen selection, engagement geometry, and activation architecture determine whether the therapy is outmanoeuvred by the biology it must defeat.
Why Coding Bio builds in the T-cell engager format
The choice is not that T-cell engagers are superior. The choice reflects two things: off-the-shelf access reaches the patients who cannot enter a CAR-T manufacturing window, and the T-cell engager format is where OR-gate escape architecture can be most precisely encoded at the molecular level — before the first patient is dosed.
A molecule designed so that each tumour-targeting arm drives killing independently — without requiring both antigens to be present simultaneously — is a different bet on the disease biology. Both arms must fail simultaneously for the tumour to escape. Each failure carries its own evolutionary fitness cost. That is an engineering decision that can be made at the design stage, in the format that reaches the patients who need it most.
The format debate will continue. The biology doesn't care which side wins. It only cares whether the molecule in front of it was designed for the problem it presents.